Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 3, 1997, Pages 287-292

  Odani, Atsuko ^a   Hashimoto, Yukiya ^a   Otsuki, Yuko ^a   Uwai, Yuichi ^a   Hattori, Haruo ^a   Furusho, Kenshi ^a   Inui, Ken Ich ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; PHENYTOIN;

ADOLESCENT; ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BAYES THEOREM; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; EPILEPSY; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; JAPAN; MUTATION; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; EPILEPSY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HETEROZYGOTE; HUMANS; INFANT; JAPAN; MALE; MIXED FUNCTION OXYGENASES; MUTATION; PHENYTOIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0030858160     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90031-X     Document Type: Article

References (17)

1. Fritz S, Lindner W, Roots I, Frey BM, Kupfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987;241:615-22.
2. Inaba T. Phenytoin: pharmacogenetic polymorphism of 4′-hydroxylation. Pharmacol Ther 1990;46:341-7.
3. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-99.
4. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
5. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
6. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
7. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991;175:1112-8.
8. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DLP, et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993;289: 533-8.
9. Wang S, Huang J, Lai M, Tsai J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995;5: 37-42.
10. Hashimoto Y, Otsuki Y, Odani A, Takano M, Hattori H, Furusho K, et al. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol Pharm Bull 1996;19: 1103-5.
11. Spielberg S, McCrea J, Cribb A, Rushmore T, Waldman S, Bjornsson T, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan [abstract]. Clin Pharmacol Ther 1996;59:215.
12. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anti-coagulation therapy. Pharmacogenetics 1995;5:389-92.
13. Hashimoto Y, Koue T, Otsuki Y, Yasuhara M, Hori R, Inui K. Simulation for population analysis of Michaelis-Menten elimination kinetics. J Pharmacokin Biopharm 1995;23:201-12.
14. Odani A, Hashimoto Y, Takayanagi K, Otsuki Y, Koue T, Takano M, et al. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull 1996;19:444-8.
15. Beal SL, Sheiner LB. NONMEM Users Guides. San Francisco: NONMEM Project Group, University of California at San Francisco, 1992.
16. de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xiao ZS, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404-11.
17. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996;24: 1401-3.